Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606781 | 0.88 | KDM4E (0.49) | KDM4EMAPTTHRBGPR119TP53 | |
| SCHEMBL18685698 | 0.84 | KDM4E (0.52) | KDM4EMAPTTHRBGPR119KMT2A | |
| SCHEMBL4235039 | 0.83 | MAPT (0.51) | KDM4EMAPTTHRBGPR119TP53 | |
| SCHEMBL5451783 | 0.82 | CCR5 (0.54) | THRBGPR119GAALMNASMN1; SMN2 | |
| SCHEMBL19937645 | 0.81 | MAPT (0.49) | KDM4EMAPTTHRBGPR119ALDH1A1 | |
| SCHEMBL5445576 | 0.81 | KDM4E (0.49) | KDM4EMAPTTHRBGPR119TP53 | |
| SCHEMBL18403235 | 0.80 | KDM4E (0.48) | KDM4EMAPTTHRBGPR119TP53 | |
| SCHEMBL5456416 | 0.80 | CCR5 (0.51) | ALDH1A1LMNACNR1 | |
| SCHEMBL7605085 | 0.80 | GPR119 (0.47) | KDM4EMAPTTHRBGPR119ALDH1A1 | |
| SCHEMBL7544743 | 0.79 | CCR5 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112940459-B | Nanocrystalline composite liquid crystal material and preparation method thereof | 苏州克里斯图材料科技有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-112940459-A | Nanocrystalline composite liquid crystal material and preparation method thereof | 苏州克里斯图材料科技有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-105164238-B | Lubricating oil composition | 出光兴产株式会社 | 2021-06-29 | — | — | CN | disclosed |
| CN-112940459-A | Nanocrystalline composite liquid crystal material and preparation method thereof | 苏州克里斯图材料科技有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-2980194-B1 | LUBRICANT OIL COMPOSITION | IDEMITSU KOSAN CO (JP) | 2020-04-01 | — | — | EP | disclosed |
| US-10563148-B2 | Lubricant oil composition | IDEMITSU KOSAN CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-9410106-B2 | Lubricating oil composition | IDEMITSU KOSAN CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20160032214-A1 | LUBRICANT OIL COMPOSITION | IDEMITSU KOSAN CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-2980194-A1 | LUBRICANT OIL COMPOSITION | Idemitsu Kosan Co., Ltd (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20150051128-A1 | LUBRICATING OIL COMPOSITION | IDEMITSU KOSAN CO., LTD. (JP) | 2015-02-19 | — | — | US | disclosed |
| EP-2826847-A1 | LUBRICATING OIL COMPOSITION | Idemitsu Kosan Co., Ltd (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | CHAMBERS MARK S | 2007-05-24 | — | — | US | disclosed |
| US-20070042918-A1 | Lubricating oil additive and lubricating oil composition | IDEMITSU KOSAN CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-7153868-B2 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. | 2006-12-26 | — | — | US | disclosed |
| EP-1686168-A1 | LUBRICATING OIL ADDITIVE AND LUBRICATING OIL COMPOSITION | IDEMITSU KOSAN CO., LTD. (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | disclosed |
| EP-0553801-B1 | Use of sulfur-containing acid phosphoric ester as internal release agent | MITSUI TOATSU CHEMICALS (JP) | 1997-04-23 | — | — | EP | disclosed |
| US-5389708-A | Polymerizing polyisocyanate or polyisothiocyanate with polyol or polythiol in presence of thiophosphoric or dithiophosphoric acid ester | MITSUI TOATSU CHEMICALS, INC. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0553801-A1 | Use of sulfur-containing acid phosphoric ester as internal release agent | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | KCNH3, KCNH2, KCNK3 | KDM4E 1083/4885MAPT 4809/4885THRB 1812/4885 |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | TACR2, KCNK3, KCNH3 | KDM4E 992/4885MAPT 4857/4885THRB 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.